More than 70 different mixed lineage leukemia (MLL) rearrangements involving 11q23 have been molecularly characterized in acute leukemia. Among these, the MLLT11 gene is highly unique as MLL fusion partner because the entire open reading frame is usually fused in-frame to the N-terminal portion of the MLL gene. By using molecular genetic methods, we identified the chromosomal fusion site within MLL exon 10 sequences which were fused to the MLLT11 intron 1 sequences. This unusual break site results in the creation of two in-frame MLL-MLLT11 fusion transcripts in this acute myeloid leukemia patient with t(1;11)(q21;q23). One fusion transcript represents a normal splice product, while the other contains intronic sequences and a cryptic splice event in order to generate an intact fusion transcript. We also reviewed all published articles which have reported t(1;11)(q21;q23) in myeloid or lymphoid neoplasm and attempted to summarize these published data. Of interest, pediatric patients displayed a significant larger portion of unique balanced translocations (n = 40), while complex karyotypes were less often identified (n = 12). Vice versa, in adult leukemia patients, complex karyotypes (n = 5) were more frequent than unique balanced translocations (n = 2).

Keywords:
Adult patients, MLL-MLLT11 rearrangement, 11q23, Splicing variants, Acute myeloid leukemia
1.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008.
2.
Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cave H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grumayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Moricke A, Schrappe M, Alonso CN, Schafer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R: New insights to the MLL recombinome of acute leukemias. Leukemia 2009;23:1490–1499.
3.
Tse W, Zhu W, Chen HS, Cohen A: A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 1995;85:650–656.
4.
Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W: Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol 2009;2:23.
5.
Tse W, Joachim Deeg H, Stirewalt D, Appelbaum FR, Radich J, Gooley T: Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br J Haematol 2005;128:218–220.
6.
Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP: Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 2004;104:3058–3063.
7.
Scharf S, Zech J, Bursen A, Schraets D, Oliver PL, Kliem S, Pfitzner E, Gillert E, Dingermann T, Marschalek R: Transcription linked to recombination: a gene-internal promoter coincides with the recombination hot spot II of the human MLL gene. Oncogene 2007;26:1361–1371.
8.
Shaffer LG, Slovak ML, Campbell LJ (eds): ISCN (2009): An International System for Human Cytogenetic Nomenclature. Basel, Karger, 2009, pp 55–96.
9.
Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S, Schoch C, Jansen MW, van Dongen JJ, Pieters R, Haas OA, Dingermann T, Klingebiel T, Marschalek R: Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 2005;102:449–454.
10.
Choi WT, Folsom MR, Azim MF, Meyer C, Kowarz E, Marschalek R, Timchenko NA, Naeem RC, Lee DA: C/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. Cancer Genet Cytogenet 2007;177:108–114.
11.
Strehl S, Konig M, Mann G, Haas OA: Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia. Blood 2001;97:805–808.
12.
So CW, Ma SK, Wan TS, Chan GC, Ha SY, Chan LC: Analysis of MLL-derived transcripts in infant acute monocytic leukemia with a complex translocation (1;11;4)(q21;q23;p16). Cancer Genet Cytogenet 2000;117:24–27.
13.
Busson-Le Coniat M, Salomon-Nguyen F, Hillion J, Bernard OA, Berger R: MLL-AF1q fusion resulting from t(1;11) in acute leukemia. Leukemia 1999;13:302–306.
14.
Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, Cao X, Obert C, Armstrong J, Zhang J, Song G, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff SA, Downing JR: Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci USA 2009;106:12944–12949.
15.
Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Zwaan CM, van den Heuvel-Eibrink MM: Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009;114:2489–2496.
16.
Otero L, Moellmann AC, Pombo-de-Oliveira MS, Ornellas MH, Pires V, Bouzas LF, Fernandez Tde S: Additional t(1;11)(q21;q23) with mixed lineage leukemia rearrangement in T-blastic crisis of a Ph-positive chronic myeloid leukemia. Eur J Haematol 2007;79:179–181.
17.
Stark B, Jeison M, Gabay LG, Mardoukh J, Luria D, Bar-Am I, Avrahami G, Kapeliushnik Y, Sthoeger D, Herzel G, Steinberg DM, Cohen IJ, Goshen Y, Stein J, Zaizov R, Yaniv I: Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel. Br J Haematol 2004;126:320–337.
18.
Rubnitz JE, Raimondi SC, Tong X, Srivastava DK, Razzouk BI, Shurtleff SA, Downing JR, Pui CH, Ribeiro RC, Behm FG: Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 2002;20:2302–2309.
19.
Satake N, Maseki N, Nishiyama M, Kobayashi H, Sakurai M, Inaba H, Katano N, Horikoshi Y, Eguchi H, Miyake M, Seto M, Kaneko Y: Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia 1999;13:1013–1017.
20.
Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F, Moorman AV, Secker-Walker LM: Ten novel 11q23 chromosomal partner sites. European 11q23 Workshop participants. Leukemia 1998;12:811–822.
21.
Archimbaud E, Charrin C, Magaud JP, Campos L, Thomas X, Fiere D, Rimokh R: Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint. Leukemia 1998;12:25–33.
22.
Brandt JT, Tisone JA, Bohman JE, Theil KS: Aberrant expression of CD19 as a marker of monocytic lineage in acute myelogenous leukemia. Am J Clin Pathol 1997;107:283–291.
23.
Taki T, Ida K, Bessho F, Hanada R, Kikuchi A, Yamamoto K, Sako M, Tsuchida M, Seto M, Ueda R, Hayashi Y: Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996;10:1303–1307.
24.
Martin PL, Look AT, Schnell S, Harris MB, Pullen J, Shuster JJ, Carroll AJ, Pettenati MJ, Rao PN: Comparison of fluorescence in situ hybridization, cytogenetic analysis, and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1996;18:113–121.
25.
Ten SK, Khor MK, Khalid H, Lin HP, Ng SC, Cheong SK, Yasmin A, Khuzaiah RR: Abnormalities of chromosome 11q in three cases of acute myeloid leukemia. Singapore Med J 1992;33:164–166.
26.
Hayashi Y, Sugita K, Nakazawa S, Abe T, Kojima S, Inaba T, Hanada R, Yamamoto K: Karyotypic patterns in acute mixed lineage leukemia. Leukemia 1990;4:121–126.
27.
Meloni-Balliet AM, Morgan R, Piatt J, Sandberg AA: Translocation t(1;11)(q21;q23), a new subgroup within M4 acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1989;37:269–271.
28.
Berger R, Le Coniat M, Derre J, Vecchione D, Pacot A, Chen SJ, Baranger L, Bernheim A: Cytogenetic studies on acute nonlymphocytic leukemia in relapse. Cancer Genet Cytogenet 1988;34:11–18.
29.
Sait SN, Raza A, Sandberg AA: A t(1;11) in acute nonlymphocytic leukemia FAB type M4. Cancer Genet Cytogenet 1987;24:181–183.
30.
Caubet JF, Gegonne A, Stehelin D, Berger R: Abnormal localization of proto-oncogene c-ets 1 in acute leukemia with translocation t(1:11)(q21:q23) (in French). CR Acad Sci III 1986;302:589–591.
31.
Mamaeva SE, Mamaev NN, Jartseva NM, Belyaeva LV, Scherbakova EG: Complete or partial trisomy for the long arm of chromosome 1 in patients with various hematologic malignancies. Hum Genet 1983;63:107–112.
32.
Kim MJ, Choi JR, Suh JT, Lee HJ, Lee WI, Park TS: Diagnostic standardization of leukemia fusion gene detection system using multiplex reverse transcriptase-polymerase chain reaction in Korea. J Korean Med Sci 2011;26:1399–1400.
33.
Yang JJ, Marschalek R, Meyer C, Park TS: Diagnostic usefulness of genomic breakpoint analysis of various gene rearrangements in acute leukemias: a perspective of long distance – or long distance inverse – PCR-based approaches. Ann Lab Med 2012;32:316–318.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.